In vitro tool to characterize adoptive immunotherapy against cancer
CompanyNovember 2017
IsoPlexis Corporation, Branford, USA(1)
Novartis Pharmaceuticals, Cambridge, USA(2)
Novartis Pharmaceuticals, Cambridge, USA(2)
Adoptive immunotherapy is a novel treatment modality for human cancers and involves the use of viral vectors to genetically modify autologous T cells to express a chimeric antigen receptor (CAR) directed against a tumor antigen. As of today, the characterization of the functional attributes of CAR-T cell products is still a challenge. In the present study, the researchers generated an in vitro method for single-cell profiling of CAR-T pre-infusion products prepared from healthy donors together with a bioinformatics tool to visualize the results. The system provides a more sensitive and comprehensive functional assessment CAR-T pre-infusion products and may provide insights into the safety and efficacy of CAR-T cell therapy.
Single-cell multiplexed cytokine profiling of CD19 CAR-T cells reveals a diverse landscape of polyfunctional antigenspecific response
Jing Zhou(1), Qiong Xue(2)
Added on: 07-26-2021
[1] https://jitc.biomedcentral.com/articles/10.1186/s40425-017-0293-7[2] https://data.jrc.ec.europa.eu/dataset/352f7dfd-05cf-434b-a96a-7e270dc76573
